ATE322493T1 - Cyclohexennukleinsäuren - Google Patents

Cyclohexennukleinsäuren

Info

Publication number
ATE322493T1
ATE322493T1 AT00990110T AT00990110T ATE322493T1 AT E322493 T1 ATE322493 T1 AT E322493T1 AT 00990110 T AT00990110 T AT 00990110T AT 00990110 T AT00990110 T AT 00990110T AT E322493 T1 ATE322493 T1 AT E322493T1
Authority
AT
Austria
Prior art keywords
dna
cyclohexenyl
cena
nucleic acids
cyclohexene
Prior art date
Application number
AT00990110T
Other languages
English (en)
Inventor
Jing Wang
Piet Herdewijn
Original Assignee
Leuven K U Res & Dev
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Leuven K U Res & Dev filed Critical Leuven K U Res & Dev
Application granted granted Critical
Publication of ATE322493T1 publication Critical patent/ATE322493T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/32—Nitrogen atom
    • C07D473/34—Nitrogen atom attached in position 6, e.g. adenine

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Fats And Perfumes (AREA)
  • Medicinal Preparation (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AT00990110T 1999-12-30 2000-12-27 Cyclohexennukleinsäuren ATE322493T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US17372899P 1999-12-30 1999-12-30

Publications (1)

Publication Number Publication Date
ATE322493T1 true ATE322493T1 (de) 2006-04-15

Family

ID=22633239

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00990110T ATE322493T1 (de) 1999-12-30 2000-12-27 Cyclohexennukleinsäuren

Country Status (7)

Country Link
EP (1) EP1244667B1 (de)
JP (1) JP2003519231A (de)
AT (1) ATE322493T1 (de)
AU (1) AU2698301A (de)
DE (1) DE60027203T2 (de)
ES (1) ES2261270T3 (de)
WO (1) WO2001049687A2 (de)

Families Citing this family (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5898031A (en) 1996-06-06 1999-04-27 Isis Pharmaceuticals, Inc. Oligoribonucleotides for cleaving RNA
US7812149B2 (en) 1996-06-06 2010-10-12 Isis Pharmaceuticals, Inc. 2′-Fluoro substituted oligomeric compounds and compositions for use in gene modulations
US9096636B2 (en) 1996-06-06 2015-08-04 Isis Pharmaceuticals, Inc. Chimeric oligomeric compounds and their use in gene modulation
AU2003291755A1 (en) 2002-11-05 2004-06-07 Isis Pharmaceuticals, Inc. Oligomers comprising modified bases for binding cytosine and uracil or thymine and their use
CA2463719A1 (en) 2003-04-05 2004-10-05 F. Hoffmann-La Roche Ag Nucleotide analogs with six membered rings
US8569474B2 (en) 2004-03-09 2013-10-29 Isis Pharmaceuticals, Inc. Double stranded constructs comprising one or more short strands hybridized to a longer strand
US8394947B2 (en) 2004-06-03 2013-03-12 Isis Pharmaceuticals, Inc. Positionally modified siRNA constructs
US7884086B2 (en) 2004-09-08 2011-02-08 Isis Pharmaceuticals, Inc. Conjugates for use in hepatocyte free uptake assays
US20080261905A1 (en) * 2004-11-08 2008-10-23 K.U. Leuven Research And Development Modified Nucleosides for Rna Interference
WO2007073149A1 (en) * 2005-12-22 2007-06-28 Keygene N.V. Alternative nucleotides for improved targeted nucleotide exchange
DK2361256T3 (da) 2008-09-24 2013-07-01 Isis Pharmaceuticals Inc Cyclohexenyl-nukleinsyreanaloger
JP6005628B2 (ja) 2010-04-28 2016-10-12 アイオーニス ファーマシューティカルズ， インコーポレーテッドＩｏｎｉｓ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ． 修飾ヌクレオシド、その類似体、およびこれらから調製されるオリゴマー化合物
DK3031920T3 (da) 2010-07-19 2019-10-14 Ionis Pharmaceuticals Inc Modulation af dystrofi myotonica-protein kinase (dmpk) ekspression
WO2012170347A1 (en) 2011-06-09 2012-12-13 Isis Pharmaceuticals, Inc. Bicyclic nucleosides and oligomeric compounds prepared therefrom
CA2838984A1 (en) 2011-06-10 2012-12-13 Isis Pharmaceuticals, Inc. Methods for modulating kallikrein (klkb1) expression
EP2726153B1 (de) 2011-06-29 2018-03-28 Ionis Pharmaceuticals, Inc. Verfahren zur modulierung der kallikrein (klkb1)-expression
AU2012308320C1 (en) 2011-09-14 2018-08-23 Translate Bio Ma, Inc. Multimeric oligonucleotide compounds
AU2012358238B2 (en) 2011-12-22 2017-12-07 C. Frank Bennett Methods for modulating Metastasis-Associated-in-Lung-Adenocarcinoma-Transcript-1(MALAT-1) expression
WO2013120003A1 (en) 2012-02-08 2013-08-15 Isis Pharmaceuticals, Inc. Modulation of rna by repeat targeting
US9340784B2 (en) 2012-03-19 2016-05-17 Ionis Pharmaceuticals, Inc. Methods and compositions for modulating alpha-1-antitrypsin expression
US9221864B2 (en) 2012-04-09 2015-12-29 Isis Pharmaceuticals, Inc. Tricyclic nucleic acid analogs
WO2013154799A1 (en) 2012-04-09 2013-10-17 Isis Pharmaceuticals, Inc. Tricyclic nucleosides and oligomeric compounds prepared therefrom
WO2013177248A2 (en) 2012-05-22 2013-11-28 Isis Pharmaceuticals, Inc. Modulation of enhancer rna mediated gene expression
ES2809199T3 (es) 2012-06-25 2021-03-03 Ionis Pharmaceuticals Inc Modulación de la expresión de UBE3A-ATS
WO2014018930A1 (en) 2012-07-27 2014-01-30 Isis Pharmaceuticals. Inc. Modulation of renin-angiotensin system (ras) related diseases by angiotensinogen
US9403865B2 (en) 2012-08-15 2016-08-02 Ionis Pharmaceuticals, Inc. Method of preparing oligomeric compounds using modified capping protocols
EP4052709A1 (de) 2012-10-11 2022-09-07 Ionis Pharmaceuticals, Inc. Verfahren zur behandlung der kennedy-krankheit
AR092982A1 (es) 2012-10-11 2015-05-13 Isis Pharmaceuticals Inc Modulacion de la expresion de receptores androgenicos
US9029335B2 (en) 2012-10-16 2015-05-12 Isis Pharmaceuticals, Inc. Substituted 2′-thio-bicyclic nucleosides and oligomeric compounds prepared therefrom
EP2951191B1 (de) 2013-01-31 2018-10-17 Ionis Pharmaceuticals, Inc. Verfahren zur herstellung oligomerer verbindungen unter verwendung von modifizierten kopplungsprotokollen
CA3170716A1 (en) 2013-02-14 2014-08-21 Ionis Pharmaceuticals, Inc. Modulation of apolipoprotein c-iii (apociii) expression in lipoprotein lipase deficient (lpld) populations
PT2992098T (pt) 2013-05-01 2019-07-05 Ionis Pharmaceuticals Inc Composições e métodos para modular a expressão de hbv e ttr
US9909124B2 (en) 2013-06-21 2018-03-06 Ionis Pharmaceuticals, Inc. Compounds and methods for modulating apolipoprotein C-III expression for improving a diabetic profile
ES2787600T3 (es) 2013-07-02 2020-10-16 Ionis Pharmaceuticals Inc Moduladores del receptor de la hormona del crecimiento
TW201536329A (zh) 2013-08-09 2015-10-01 Isis Pharmaceuticals Inc 用於調節失養性肌強直蛋白質激酶(dmpk)表現之化合物及方法
RU2712559C9 (ru) 2013-08-28 2020-10-08 Ионис Фармасьютикалз, Инк. Модуляция экспрессии прекалликреина (пкк)
EP3043827B1 (de) 2013-09-13 2019-07-03 Ionis Pharmaceuticals, Inc. Inhibitoren des komplementfaktors b
PT3087183T (pt) 2013-12-24 2020-10-08 Ionis Pharmaceuticals Inc Modulação da expressão da proteína relacionada com angiopoietina 3
US10036019B2 (en) 2014-03-17 2018-07-31 Ionis Pharmaceuticals, Inc. Bicyclic carbocyclic nucleosides and oligomeric compounds prepared therefrom
DK3757214T3 (da) 2014-04-01 2022-07-04 Biogen Ma Inc Sammensætninger til modulering af sod-1-ekspression
US10221416B2 (en) 2014-04-24 2019-03-05 Ionis Pharmaceuticals, Inc. Oligomeric compounds comprising alpha-beta-constrained nucleic acid
EP3647318B1 (de) 2014-04-28 2021-06-30 Ionis Pharmaceuticals, Inc. Verbindungsmodifizierte oligomerverbindungen
SI3137605T1 (sl) 2014-05-01 2021-02-26 Ionis Pharmaceuticals, Inc. Sestavki in metode za modulacijo ekspresije angiopoetin 3-podobnega
PE20170010A1 (es) 2014-05-01 2017-03-04 Ionis Pharmaceuticals Inc Composiciones y metodos para modular la expresion del factor b del complemento
BR112016022855B1 (pt) 2014-05-01 2022-08-02 Ionis Pharmaceuticals, Inc Compostos e composições para modular a expressão de pkk e seus usos
CA2942570A1 (en) 2014-05-01 2015-11-05 Ionis Pharmaceuticals, Inc. Compositions and methods for modulating growth hormone receptor expression
WO2016040589A1 (en) 2014-09-12 2016-03-17 Alnylam Pharmaceuticals, Inc. Polynucleotide agents targeting complement component c5 and methods of use thereof
EP3207138B1 (de) 2014-10-17 2020-07-15 Alnylam Pharmaceuticals, Inc. Gegen aminolävulinsäuresynthase-1 (alas1) gerichtete polynukleotidmittel und verwendungen davon
WO2016069694A2 (en) 2014-10-30 2016-05-06 Alnylam Pharmaceuticals, Inc. Polynucleotide agents targeting serpinc1 (at3) and methods of use thereof
WO2016086104A1 (en) 2014-11-25 2016-06-02 Ionis Pharmaceuticals, Inc. Modulation of ube3a-ats expression
US9688707B2 (en) 2014-12-30 2017-06-27 Ionis Pharmaceuticals, Inc. Bicyclic morpholino compounds and oligomeric compounds prepared therefrom
WO2016137923A1 (en) 2015-02-23 2016-09-01 Ionis Pharmaceuticals, Inc. Method for solution phase detritylation of oligomeric compounds
BR112017017178A2 (pt) 2015-02-26 2018-04-03 Ionis Pharmaceuticals Inc moduladores específicos de alelo de rodopsina de p23h
MX2017012610A (es) 2015-04-08 2018-03-16 Alnylam Pharmaceuticals Inc Composiciones y metodos para inhibir la expresion del gen lect2.
ES2791995T3 (es) 2015-04-16 2020-11-06 Ionis Pharmaceuticals Inc Composiciones para modular la expresión de C90RF72
EP3310918B1 (de) 2015-06-18 2020-08-05 Alnylam Pharmaceuticals, Inc. Gegen hydroxysäureoxidase (glycolat-oxidase, hao1) gerichtete polynukleotidwirkstoffe und verfahren zur verwendung davon
SG10202003148VA (en) 2015-10-08 2020-05-28 Ionis Pharmaceuticals Inc Compounds and methods for modulating angiotensinogen expression
AU2016349625B2 (en) 2015-11-06 2022-07-07 Ionis Pharmaceuticals, Inc. Modulating apolipoprotein (a) expression
CA3131700A1 (en) 2019-02-27 2020-09-03 Ionis Pharmaceuticals, Inc. Modulators of malat1 expression
MX2021011916A (es) 2019-03-29 2021-10-26 Ionis Pharmaceuticals Inc Compuestos y metodos para modular ube3a-ats.
KR20210142699A (ko) 2019-03-29 2021-11-25 미쓰비시 타나베 파마 코퍼레이션 Dux4의 발현을 조절하기 위한 화합물, 방법 및 의약조성물
EP4121534A1 (de) 2020-03-18 2023-01-25 Alnylam Pharmaceuticals, Inc. Zusammensetzungen und verfahren zur behandlung von patienten mit einer heterozygoten alaninglyoxylat-aminotransferase-genvariante (agxt)
JPWO2021230286A1 (de) 2020-05-12 2021-11-18
KR20230108728A (ko) 2020-11-18 2023-07-18 아이오니스 파마수티컬즈, 인코포레이티드 앤지오텐시노겐 발현을 조절하기 위한 화합물 및 방법
TW202333748A (zh) 2021-07-19 2023-09-01 美商艾拉倫製藥股份有限公司 用於處置具有或有風險發展非原發性高草酸鹽尿疾病或病症的個體的方法及組成物

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5034506A (en) * 1985-03-15 1991-07-23 Anti-Gene Development Group Uncharged morpholino-based polymers having achiral intersubunit linkages
DE19815901A1 (de) * 1998-04-08 1999-10-14 Aventis Res & Tech Gmbh & Co Verfahren zur Herstellung von Pentopyranosyl-Nucleosiden

Also Published As

Publication number Publication date
WO2001049687A2 (en) 2001-07-12
WO2001049687A9 (en) 2002-09-06
WO2001049687A3 (en) 2002-03-28
EP1244667B1 (de) 2006-04-05
ES2261270T3 (es) 2006-11-16
AU2698301A (en) 2001-07-16
EP1244667A2 (de) 2002-10-02
DE60027203T2 (de) 2007-01-04
JP2003519231A (ja) 2003-06-17
DE60027203D1 (de) 2006-05-18

Similar Documents

Publication Publication Date Title
ATE322493T1 (de) Cyclohexennukleinsäuren
US11634451B2 (en) Method for the site-specific enzymatic labelling of nucleic acids in vitro by incorporation of unnatural nucleotides
Miller et al. The nucleotide sequence of oocyte 5S DNA in Xenopus laevis. II. The GC-rich region
Hagenbüchle et al. Conservation of the primary structure at the 3′ end of 18S rRNA from eucaryotic cells
Yoo et al. 2′‐O‐methyl‐modified phosphorothioate antisense oligonucleotides have reduced non‐specific effects in vitro
Braich et al. Regiospecific solid-phase synthesis of branched oligonucleotides. Effect of vicinal 2 ‘, 5 ‘-(or 2 ‘, 3 ‘-) and 3 ‘, 5 ‘-phosphodiester linkages on the formation of hairpin DNA
MXPA05001355A (es) Formas nuevas adicionales de moleculas de arn de interferencia.
CN116287127A (zh) 用于检测靶rna的方法和组合物
ATE293123T1 (de) Bi- und tri-zyklische - nukleosid, nukleotid und oligonukleotid-analoga
Gryaznov et al. RNA mimetics: oligoribonucleotide N3′→ P5′ phosphoramidates
JP2002514080A (ja) 酵素ｄｎａ分子
Beaudry et al. An efficient strategy for the synthesis of circular RNA molecules.
Svinarchuk et al. An Unusually Stable Purine (Purine-Pyrimidine) Short Triplex.: THE THIRD STRAND STABILIZES DOUBLE-STRANDED DNA∗
Xiong et al. Transcriptional slippage during the transcription initiation process at a mutant lac promoter in vivo
Nashimoto Conversion of mammalian tRNA 3′ processing endoriubonuclease to four-base-recognizing RNA cutters
Grant et al. Sequence-specific alkylation and cleavage of DNA mediated by purine motif triple helix formation
Frieden et al. Tightening the belt on polymerases: evaluating the physical constraints on enzyme substrate size
Deng et al. Factor-dependent release of nascent RNA by ternary complexes of vaccinia RNA polymerase
Frech et al. Uridine insertion into preedited mRNA by a mitochondrial extract from Leishmania tarentolae: stereochemical evidence for the enzyme cascade model
Compagno et al. Antisense oligonucleotides containing modified bases inhibit in vitro translation of Leishmania amazonensis mRNAs by invading the mini-exon hairpin
Daniher et al. Precise control of RNA cleavage by ribozyme mimics
Carriero et al. Template-mediated synthesis of lariat RNA and DNA
DE69902799T2 (de) Von kreisförmiger Matrize abhängige Kettenreaktion
EP0931090B1 (de) Verbesserte chimäre oligonukleotidvektoren
WO2005010188A3 (en) Rnas able to modulate chromatin silencing

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties